Literature DB >> 23471844

Rifaximin is an efficacious treatment for the Parkinsonian phenotype of hepatic encephalopathy.

Beverley Kok1, Matthew R Foxton, Christopher Clough, Debbie L Shawcross.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23471844     DOI： 10.1002/hep.26364

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  3 in total

1.  Acquired Hepatocerebral Degeneration After a Splenorenal Shunt in the Sub-Saharan Africa Context: A Case Report and Brief Review of Literature.

Authors:  Abdu Mohammed; Abate Bane; Getahun Mengistu; Fekadu Ayalew; Amir Sultan Seid
Journal:  Cureus       Date:  2022-03-11

Review 2.  Peripheral aetiopathogenic drivers and mediators of Parkinson's disease and co-morbidities: role of gastrointestinal microbiota.

Authors:  Sylvia M Dobbs; R John Dobbs; Clive Weller; André Charlett; Aisha Augustin; David Taylor; Mohammad A A Ibrahim; Ingvar Bjarnason
Journal:  J Neurovirol       Date:  2015-06-20       Impact factor: 2.643

3.  Uncommon Movement Disorders in Chronic Hepatic Disease with Response to Rifaximin.

Authors:  Ana L Sousa; Paula Salgado; José E Alves; Sara Silva; Sofia Ferreira; Marina Magalhães
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2019-08-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.